Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label, Single-Center Study to Assess Pharmacokinetic Characteristics and Safety of Endari in Patients With Sickle Cell Disease

NCT04684381 is registered in ClinicalTrials.gov with Emmaus Medical, Inc. as lead sponsor.

NCT NCT04684381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label, Single-Center Study to Assess Pharmacokinetic Characteristics and Safety of Endari in Patients With Sickle Cell Disease
Lead sponsor
Emmaus Medical, Inc.
Phase
Phase 4
Overall status
Completed
Start date
January 4, 2021
Completion date
June 30, 2021
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, sickle cell disease